12.png)
Dornier MedTech America, a global medical device company and the pioneer of Extracorporeal Shock Wave Lithotripsy (ESWL), has received FDA clearance to market the Delta III. This is the latest generation of the world's best-selling and most clinically cited lithotripter, the Delta II.
The Delta III reflects Dornier's continued commitment to developing the most cutting-edge solutions for kidney stone treatment. Compared to its predecessor, the Delta III provides improvements of: Powerful IMAGING (for improved stone visualization), Maximized ENERGY (to treat more stones in more patients), Enhanced EFFICIENCY (with time saving features to serve more patients).
Powerful IMAGING: the system provides improved imaging quality with 400%2 more power and two imaging modalities (Ultrasound or X-ray) for better stone visibility.
Maximized ENERGY: the New 180 EMSE (+25% larger2) delivers more power for enhanced penetration depth to treat larger patients. In a 183 patient clinical study, the new 180 EMSE was shown to deliver a similar 95% stone free success rate – for patients with BMI higher than 25, as with patients with BMI below 25.3 Combined with Dornier's exclusive Opticouple, an optical camera system, visualized air bubbles are removed in the coupling gel at the interface of the therapy head and patient's skin via the user. Clinical research4 shows a 43% increase in effectiveness with less shock waves energy needed per treatment.
Enhanced EFFICIENCY: Additionally, the Delta III increases ease of use and improves time saving workflow with its patent protected Unified Hand Control with precise fingertip control of the lithotripter, table and X-ray C-arm movements.
The Delta III is made in Munich, Germany
Dornier medtech's, treatment lithotripter, delta iii receives us fda marketing approval
2.jpg)
